A fresh study finds that an older class of antipsychotic medications can
lower blood sugar in people with type 2 diabetes.
These drugs may address the needs of people who cannot take existing
diabetes medications, or for whom they have become less effective.The
antipsychotics address the expression of an enzyme that has recently been
tied to hyperglycemia in mice.With type 2 diabetes (T2D) on the rise there is an expanding need for
effective treatments. Researchers from the University of Alberta (UAlberta)
in Canada have been exploring existing non-diabetes drugs as new
therapeutic options for people with T2D. The study has found that a class
of older antipsychotic drugs reduces blood sugar levels by targeting an
enzyme tied to hyperglycemia in diabetes.
lower blood sugar in people with type 2 diabetes.
These drugs may address the needs of people who cannot take existing
diabetes medications, or for whom they have become less effective.The
antipsychotics address the expression of an enzyme that has recently been
tied to hyperglycemia in mice.With type 2 diabetes (T2D) on the rise there is an expanding need for
effective treatments. Researchers from the University of Alberta (UAlberta)
in Canada have been exploring existing non-diabetes drugs as new
therapeutic options for people with T2D. The study has found that a class
of older antipsychotic drugs reduces blood sugar levels by targeting an
enzyme tied to hyperglycemia in diabetes.
The enzyme the drugs inhibit is succinyl CoA:3-ketoacid CoA transferase or
SCOT. The drugs belong to the diphenyl butyl piperidines medication class,
abbreviated as DPBP.
